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ABSTRACT: Glycosaminoglycan-based hydrogels hold great
potential for applications in tissue engineering and regenerative
medicine. By mimicking the natural extracellular matrix processes
of growth factor binding and release, such hydrogels can be used as
a sustained delivery device for growth factors. Since neural
networks commonly follow well-defined, high-aspect-ratio paths
through the central and peripheral nervous system, we sought to
create a fiber-like, elongated growth factor delivery system.
Cryogels, with networks formed at subzero temperatures, are
well-suited for the creation of high-aspect-ratio biomaterials,
because they have a macroporous structure making them
mechanically robust (for ease of handling) yet soft and highly
compressible (for interfacing with brain tissue). Unlike hydrogels,
cryogels can be synthesized in advance of their use, stored with ease, and rehydrated quickly to their original shape. Herein, we use
solvent-assisted microcontact molding to form sacrificial templates, in which we produced highly porous cryogel microscale scaffolds
with a well-defined elongated shape via the photopolymerization of poly(ethylene glycol) diacrylate and maleimide-functionalized
heparin. Dissolution of the template yielded cryogels that could load nerve growth factor (NGF) and release it over a period of 2
weeks, causing neurite outgrowth in PC12 cell cultures. This microscale template-assisted synthesis technique allows tight control
over the cryogel scaffold dimensions for high reproducibility and ease of injection through fine gauge needles.
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■ INTRODUCTION
Growth factors have received much attention for applications
in tissue engineering and regenerative medicine for their ability
to affect cellular behavior and promote regeneration of
damaged tissue. For example, in the field of neuroscience,
several growth factors have been shown to be neuroprotective
and are being investigated for therapeutic applications in
Alzheimer’s disease,1 Parkinson’s disease,2,3 and spinal cord
injury4 to name just a few. One major limitation of the use of
growth factors is that they require repeat/frequent admin-
istrations due to their inherent short half-life (lack of serum
stability).2 As such, pioneering research has developed protein
pumps for the continual delivery, for example, of glial cell-line-
derived neurotrophic factor to the brains of Parkinson’s disease
patients to protect their dopaminergic neurons from the
natural pathological progression of the disease.2,5
Hydrogels have been proposed as an alternative delivery
system, releasing growth factors more slowly to the
surrounding tissue than a bolus injection. To achieve sustained
release of drugs and growth factors from biomaterials, our lab
and others have incorporated heparin into the hydrogel
structure.6−9 Heparin is known to bind a wide variety of
growth factors with varying degrees of affinity, so it represents
an ideal means of functionalizing hydrogels to increase loading
and control the release of growth factors.
In order to incorporate heparin into hydrogels, the carboxyl
groups on the heparin repeating unit can be reacted with
amine groups on a cross-linker such as amine-terminated
poly(ethylene glycol) (PEG) via an N-(3-(dimethylamino)-
propyl)-N′-ethylcarbodiimide (EDC)/N-hydroxysulfosuccini-
mide (sNHS)-assisted reaction.10,11 While this forms a stable
covalent bond within biohybrid materials, the use of EDC and
sNHS to assist the cross-linking process does not allow for in
situ applications in the presence of cells due to toxicity issues.
To overcome this drawback, the carboxyl groups of heparin
can alternatively be modified to contain maleimide groups
(again via EDC/NHS carboxyl−amine coupling). This
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maleimide-functionalized heparin can then be purified ready
for use with thiol-containing compounds such as thiol-
terminated multiarm PEG.12 This allows the addition of cells
and growth factors to either of the gel components in their
premixed state, which then forms a gel once combined and
mixed. Despite much improvement in the synthesis and
application of injectable hydrogels, they also carry an inherent
drawback for use in tissue with little interstitial space (such as
the brain), which is that they occupy almost the entire
injection volume (nonmacroporous) and therefore create a
dead space.7 Cell penetration into the gel is therefore subject
to gel degradation. A further improvement over standard in situ
forming hydrogels has been to fabricate microspheres that can
be injected but annealed together to form a scaffold. In such
cases, cells can grow throughout the spaces between the
spheres (microporous scaffold) before degradation has taken
place.13,14 However, in this case, the microspheres still occupy
a large dead space until they are degraded.13
Macroporous scaffolds, with fine hydrogel struts and large
interconnecting pores, offer a means of creating preformed,
injectable materials without a large dead volume. Cryogelation
represents a simple, but highly effective, method for producing
such scaffolds, whereby the hydrogel components are frozen
before/during network formation. Ice crystals form in the
reaction mixture, thus cryoconcentrating the reactants between
the ice crystals where they cross-link to form the hydrogel
network. Once the ice is removed, a pore remains where the
ice crystal was previously.10,11 The resulting materials, termed
cryogelated hydrogels or cryogels, contain struts of hydrogel
and large, interconnecting pores. Cryogel materials can be
injected through needles with an inner diameter much smaller
that the width of the material, since it compresses like a sponge
and re-expands to its original volume and shape once through
the needle.15−17
Cryogels are typically quite robust, exhibiting good tough
mechanical properties, making them easy to handle for
applications in ex vivo slice culture18,19 and local delivery.20
However, in addition, their ability to be compressed through
an injection cannula is of interest for use in the brain,21 where
surgical intervention is limited. Unlike spherical microscale
cryogels (termed microcarriers) developed for cell culture22/
cell transplantation,11 this work aimed to produce high-aspect-
ratio, fiber-like cryogels as a step toward bridging anatomically
connected regions of the brain or nervous system. For example,
using an extrusion style of injection,23 one could envisage
laying a line of fibers along the nigrostriatal pathway affected
by Parkinson’s disease in a manner similar to “bridge grafts”.24
We hypothesized that strict size control could be achieved by
forming the cryogels within well-defined sacrificial templates
(Figure 1). Templates containing channels, micrometers in
width and depth but millimeters in length, would allow the
formation of long cryogels that could still be injected through
fine gauge needles. We herein show that photoinitiated
polymerization can be used as a quick and convenient method
to cross-link maleimide-modified heparin and PEGDA after the
precursor solution has been frozen, forming biohybrid cryogels
that can load and release NGF.
■ RESULTS AND DISCUSSION
Microstructured polystyrene templates were produced by
solvent-assisted microcontact molding using PDMS stamps
that were created from three different silicon masters. These
Figure 1. Schematic depiction of the cryogel synthesis process, showing the maleimide-functionalized heparin and poly(ethylene glycol) diacrylate,
the process of template filling, subzero polymerization, thawing, and template removal.
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templates were 10 × 10 mm with channels of 70, 100, or 150
μm in width and a depth of 40 μm as determined by
multipinhole confocal microscopy (Figure 2a,c,e and Support-
ing Information, Figures S1−S3). The precursor solution
containing maleimide-functionalized heparin, poly(ethylene
glycol) diacrylate (PEGDA), the photoinitiator, and the
fluorescent label was added into the plasma-treated template
as depicted in Figure 1. Freezing the solution-filled template at
−20 °C for 30 min allowed ice crystal formation in the
solution, and subsequent cross-linking via the application of
UV light (3 min) resulted in a cross-linked polymer network
that could be thawed and then removed from the template via
THF dissolution.
Multipinhole confocal microscopy and scanning electron
microscopy of the cryogels within the template revealed that
while dehydrated they have a compacted structure that spans
the length and width of the template but not the full height/
depth (Figure 2b,d,f). Along the centerline of the channel, the
cryogel is quite flattened to the template surface as shown by
the profile measurements in Figure 2d and Supporting
Figure 2. Analysis of the templates containing channels 40 μm deep and 100 μm wide. Multipinhole confocal microscopy analysis of the
polystyrene template empty (a) or filled post polymerization (b) with corresponding profile analysis (c,d) of the empty and filled templates,
respectively. Scanning electron microscope image of an empty template (e) and a filled template (f). Confocal laser fluorescence microscope image
(g) of the filled template in the PBS hydrated state showing lines of macroporous cryogel scaffolds.
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Information, Figures S1b, S2b, and S3b. However, once the
structure is hydrated in PBS and imaged by fluorescence
confocal microscopy, the cryogels swell approximately to the
full height/depth without the appearance of a meniscus-like
shape (Figure 2g).
It should be noted here that the wavelength of UV light
chosen for the photoinitiation (366 nm) did not photobleach
the samples, since the far-red (610 nm) ATTO dye was chosen
for the cryogel functionalization. Although we have not tried,
one could envisage that commonly used dyes with lower
excitation wavelengths (e.g., 305−488 nm) may get photo-
bleached during the cross-linking process. A low-wavelength
UV lamp and a corresponding photoinitiator such as 2-
hydroxy-2-methylpropiophenone25 (large absorption band at
245 nm) would allow the use of green and near-red fluorescent
labels.
Raman spectroscopy analysis of unlabeled cryogels in
comparison to the free reagents (PEGDA and heparin
maleimide) shows that the photoinitiated cross-linking
reactions indeed exhaust the acrylate and maleimide groups
(Supporting Information, Figures S4 and S5). The peak due to
the maleimide in heparin maleimide (C=O: 1774 cm−1) is
reduced. Likewise, the characteristic peaks due to the acrylate
in PEGDA (C=C: 1640 cm−1, C=O: 1723 cm−1) are
completely reduced and blue-shifted (1732 cm−1), which
occurs as a result of the radical polymerization of PEGDA.
Additionally, the presence of the characteristic sulfate group
(R−O−SO3−) vibrations of heparin (890, 1070 cm−1) in the
spectrum, show its successful incorporation into the cryogel
network. However, these data cannot rule out the possibility
that we have formed two separate interpenetrating networks of
PEGDA and heparin.
Since heparin is a highly negatively charged molecule due to
its sulfate groups, we sought to analyze the distribution of the
heparin throughout the cryogel by using a positively charged
fluorescent molecule (doxorubicin) that can electrostatically
bind to heparin but not PEG.26 Supporting Figure S6 shows
that fluorescence of labeled heparin shown in green largely
overlaps with that of bound doxorubicin (red), showing that
heparin is distributed throughout the cryogel, though there are
areas of slightly higher intensity than others. A good
correlation between the two fluorescent signals was observed
as shown by a Pearson’s R value of 0.74 (where +1 shows
perfect correlation, 0 shows no correlation, and −1 shows
anticorrelation).
Ice crystal formation, prior to polymer network formation, is
a useful means to form macroporous structures in hydrogel
materials. Using ice as a porogen has the advantages of being
easy to wash out, with no porogen additives needed, and the
pore size can be varied by changing the rate of cooling.27
However, the pore size distribution is rather large, which could
be disadvantageous if a fixed pore size is required. Scanning
electron microscopy of a dehydrated scaffold (Figure 3a,b and
Supporting Information, Figure S7) shows the macroporous
structure of the cryogel. However, we evaluated the pore size
distribution in the more physiologically relevant hydrated state
using confocal laser scanning microscopy (CLSM). Supporting
Figure S8 illustrates the pore size distribution based on the
CLSM measurements for these microscale cryogel scaffolds,
with an average pore diameter of 9.9 μm. By varying the
Figure 3. Scanning electron microscopy analysis of a heparin-based cryogel scaffold in its dehydrated state (a,b) showing the porous nature of the
scaffold. Fluorescence microscopy analysis of ATTO-610-labeled cryogel scaffolds in their hydrated state, which had been synthesized in 70 μm
channels (c), 100 μm channels (d), and 150 μm channels (e) showing the high precision control over scaffold dimensions.
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Figure 4. Loading and release of nerve growth factor (NGF) from the heparin-based microscale cryogel scaffolds. (a) shows that almost all of the
NGF was loaded from the loading solutions (500 ng/mg of cryogel or 1000 ng/mg of cryogel) to the cryogel scaffold and was slowly released (b)
over a period of 2 weeks (longest time analyzed) (n = 3) (error bars represent the cumulative value of standard deviation).
Figure 5. Analysis of the bioactivity of the released NGF. Fluorescence microscopy analysis of PC12 cells (blue = nuclear stain Hoechst, green =
anti-βIII-tubulin staining) grown in the absence of NGF (a) show that almost no neurites can be observed, whereas the addition of NGF to the
culture medium at a concentration of 50 ng/mL (b) causes long neurites to extend from the cell bodies. PC12 cells cultured in the presence of
NGF-loaded cryogels (c) also show neurite extensions as quantified by analysis of the longest neurite lengths per cell (d) (error bars represent ±
standard error of the mean (100 neurites measured)). An example light microscope image (e) of the PC12 cells cultured in the presence of NGF-
loaded cryogels showing some cells adherent to the tissue culture plastic and some attached to the cryogel. (f−i) Fluorescence microscopy of the
cells attached to the ATTO-610-labeled cryogel (red) as observed via a Hoechst nuclear stain (blue) and anti-βIII-tubulin staining (green) showing
small projections from the cells into the cryogel structure.
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dimensions of the template, the size of the resulting cryogel
can be precisely controlled (Figure 3). Three different
templates were used with channel widths of 70 μm (Figure
3c), 100 μm (Figure 3d), and 150 μm (Figure 3e). The μ-
contact printing method of template formation allows well-
defined and reproducible cryogel shapes to be formed without
the need for punching out shapes form a bulk cryogel
scaffold.21 While cryogels from millimeter-sized molds have
been injected through a 16 gauge needle,15,16 herein we aimed
to create high-aspect-ratio materials with precise microscale
widths. The macroporous structure and small width of the
cryogels formed herein allow them to be injected through a
much smaller needle (30 gauge) (Supporting Information,
Figure S9). Additionally, in principle, one can envisage the use
of this technique for disc or other shaped materials as defined
by the silicon master and corresponding template.
Design flexibility in terms of the size and shape of the
cryogel scaffolds broads the range of potential end-user
applications. For example, when using cylinder-shaped
PEGDA cryogels to deliver a demyelinating agent to central
nervous system slice cultures, smaller cryogels were used for
the spinal cord sections than the larger cortical sections.18
Where either whole neural pathways or large brain areas are to
be targeted, high-aspect-ratio scaffolds may be able to bridge
across regions. Although application of elongated cryogels to
ex vivo coslice models (such as the Parkinson’s disease relevant
nigrostriatal pathway28) has recently been achieved,29 in vivo
application would likely require sophisticated injection/
extrusion techniques.23
The use of the highly sulfated glycosaminoglycan heparin in
biomaterials allows noncovalent, electrostatic/reversible bind-
ing of growth factors followed by sustained release over
extended periods of time.7,11,30 Herein, the uptake of NGF to
the cryogels was assessed at two different concentrations of
either 500 or 1000 ng of NGF per 1 mg of cryogel (Figure 4).
These amounts of NGF were chosen, because we have
previously shown that heparin-based microcarriers release less
than 3% of their growth factor payload,11 thus requiring a high
loading amount to see a biological effect in a short time frame.
While the literature cites NGF as only having low/moderate
affinity toward heparin,31,32 the cryogels took up almost all the
NGF from both concentrations of the solution (94.5% for 500
ng/mg and 96.6% for 1000 ng/mg).
The release of bound NGF into PBS was measured over a
period of 2 weeks, and the cumulative release profile is plotted
in Figure 4b. This shows that for the cryogels loaded with 500
ng of NGF per 1 mg of cryogel, a plateau was reached after 3
days, whereas for the sample loaded with more NGF (1000
ng/mg), the release continues slowly from 3 to 14 days. The
released NGF after 2 weeks represents 0.5 and 0.8% of the
total NGF loaded to the cryogels (Supporting Information,
Figure S10), which is approximately in line with results
previously obtained from heparin-based microcarriers.11 The
high amount and rapid loading of NGF, together with the slow
release, indicate that NGF has sufficient affinity toward heparin
to allow for sustained delivery from these heparin-based
cryogels.
To analyze whether NGF released from the cryogels is
bioactive, cryogels were loaded with NGF at a higher
concentration (1000 ng/mg of cryogel) and placed into a
culture of PC12 cells (Figure 5). Despite being derived from a
pheochromocytoma of the rat adrenal medulla, PC12 cells are
commonly used as a model neuron, as they produce neurites
when exposed to NGF.33 As with such immortalized cell types,
care must be paid when drawing conclusions from their use;
however, herein they were used as a means of assessing the
bioactivity of the released growth factor.
Figure 5 shows PC12 cells stained with antibodies against
βIII-tubulin (also referred to as Tuj-1), a protein associated
with microtubule stability in neurons. Cells grown in the
Figure 6. PC12 cells extend neurites along NGF-loaded cryogel scaffolds. Fluorescence microscopy of PC12 cells attached to the ATTO-647-
labeled cryogel (c,g, red) as observed via Hoechst nuclear stain (a,e, blue) and anti-βIII-tubulin staining (b,f, green) with the channels merged (d,h)
showing neurites from the cells projecting along the cryogel structure (indicated by white arrows).
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absence of NGF showed the typical rounded morphology
(Figure 5a), but cells treated with NGF added directly to the
medium at a concentration of 50 ng/mL (Figure 5b) for 7 days
had neurite extensions. In addition, cells exposed to/in contact
with NGF-loaded cryogels also extended neurites as shown in
Figure 5c. Analysis of the length of the longest neurites for
each cell showed that there was no significant difference
between those cells treated with the NGF protein in solution
and those exposed to the NGF-loaded cryogels (Figure 5d),
despite in vitro release being minimal. We had previously
questioned the therapeutic utility of such a delivery device
when such a little amount of NGF is released, though we
would predict higher release rates in vivo due to competitive
binding of other serum/extracellular proteins displacing NGF.
Nevertheless, these results indicate that NGF-loaded scaffolds
can cause cellular differentiation, at least in the in vitro PC12
cell model.
Interestingly, we observed that quite a number of the cells
had migrated from the well bottom (where they had been
allowed to adhere before beginning the experiment) onto the
cryogels. An example light microscope image (Figure 5e)
shows cells that are adhered to the well plate and cells that are
attached to one of the cryogels in culture. This is intriguing,
since the cryogels have not been functionalized to improve cell
adhesion (e.g., coating with poly-D-lysine (PDL) or addition
of cell adhesion ligands). Furthermore, fluorescent microscopy
analysis of the cryogels that had cells migrated onto them
showed that while the majority of cells stayed in a round form,
a few had produced neurites that penetrated into the porous
structure of the cryogel (Figure 5f−i). Figure 6 shows that
some of the PC12 cells even extended neurites along the
outmost surface of the NGF-loaded cryogels. For applications
in directing nerve regrowth such as spinal cord injury or
peripheral nerve injury, one could consider functionalizing the
scaffold with a cell adhesion ligand such as arginine−glycine−
aspartate (RGD),34 which allows multiple cell types to adhere
to cryogel surfaces22 as this may further improve neurite
extensions through these NGF-loaded matrices.
These loading, release, and cell culture studies show that
bioactive NGF can be released up to at least 2 weeks; however,
since only a small proportion of the NGF is released, the
cryogels effectively retain a large amount of the growth factor.
If faster NGF release would be required, the heparin could first
be subjected to selective desulfation procedures, to remove
some of the sulfate groups allowing quicker protein
release.35−37
Although we have mentioned some uses of cryogel scaffolds
in ex vivo slice culture, they may also hold potential for
neurotherapeutic delivery to the brain. There are a range of
growth factors that give rise to neuroprotection or have
regenerative effects, so improving the spatial and temporal
control over their delivery is of interest.38 Unlike the spinal
cord, where macroscopic nerve guiding conduits have been
implemented to promote and guide axonal growth through the
neuroinhibitory glial scar,39−41 restricted surgical access to the
brain requires the use of injectable delivery devices. Studies
have utilized growth factor secreting cells encapsulated in a
hydrogel42,43 as a means of delivering growth factors to the
brain with the clear advantage of continual production for as
long as the grafted cells remain viable. The injection of these
cells has typically been unifocal, resulting in approximately
even delivery to the regions surrounding the graft.43 However,
there are instances where guiding neural regeneration in the
brain may be of therapeutic interest. For example, in
Parkinson’s disease where dopaminergic neurons die back
from the striatum (cell terminals) to the substantia nigra
(where the cell bodies reside), researchers have proposed using
a “nigrostriatal bridge” to promote regeneration of neuronal
networks following cell transplantation to the substantia
nigra.24,44,45
One of these early studies used fibroblast-growth-factor-4-
transfected RN-22 schwannoma cells injected so as to form a
line between a dopaminergic cell graft in the substantia nigra
and the striatum.24,46 A bridge graft up to 1.5 cm was shown to
contain many axons from the dopaminergic graft growing
toward, and projecting into, the striatum.46 There has not been
extensive study of using materials for such a purpose, although
the host response to high-aspect hydrogels placed in the
nigrostriatal pathway has been analyzed.47 Elongated, or fiber-
like, cryogel scaffolds represent an alternative to the more
abundantly studied classical hydrogel. The porous nature not
only avoids occupation of a large dead space in the brain (as
neurites can grow into the scaffold) but also allows a
predefined, preformed, but compressible shape to be injected.
This work shown herein shows the first steps toward injectable
cryogel materials that could be used for a “bridging”
application.
In summary, we have photopolymerized PEGDA with
maleimide-modified heparin within a well-defined polystyrene
template. The reactants were first frozen so that the ice crystals
that formed subsequently left behind pores in the structure.
The photopolymerization occurred successfully at a subzero
temperature to yield porous cryogel scaffolds of exact diameter
and depth in a variable microstructured shape. The use of UV
light did not photobleach the fluorescent ATTO 610 label that
was used to functionalize the scaffold. The scaffolds could be
loaded with large amounts of NGF, and a small percentage of
this could be released over a period of 2 weeks causing neurite
outgrowth in a PC12 cell culture model. In contrast to
hydrogels, these microscale cryogels exhibited excellent
mechanical properties and could retain their shape and
integrity after injection through a needle routinely used for
intracranial delivery. These data show that cryogels can be
synthesized on the microscale in a precise manner, opening the
door for further investigation into their use as a delivery device
for growth factors to the brain or spinal cord.
■ MATERIALS AND METHODS
Fabrication of the Sacrificial Polystyrene Template. Poly-
styrene templates were produced via a similar method as reported by
Müller et al.48 Silicon masters featuring channels 10 mm in length, 40
μm in depth, and either 70, 100, or 150 μm in width were created
using photolithographic etching (GeSiM, Germany). From these
silicon masters, a poly(dimethylsiloxane) silicone (PDMS) (Sylgard
184 silicone elastomer kit, Dow Corning, Germany) stamp (i.e.,
inverse of the master features) was created within polycarbonate
holders (GeSiM) by curing the PDMS (10:1 curing agent to
prepolymer) at 80 °C for 2 h. The PDMS stamp was loaded to a μ-
contact printer (GeSiM) and wetted with 30 μL of ethyl acetate
(Sigma, Germany). The stamp was then immediately lowered to a
fixed position, where it was pressed onto a flat clear polystyrene sheet
with a thickness of 40 μm (Evergreen Scale Models, USA). After 15
min at 21 °C, the PDMS stamp was raised, and the microstructured
polystyrene sheet was removed.
Template Characterization. The dimensions and the top-
ography of the polystyrene template were analyzed via multipinhole
confocal microscopy utilizing a μsurf explorer (NanoFocus AG,
Germany) equipped with a 10× objective (Olympus, Germany). 3D
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height maps were generated using μSoft analysis software (Nano-
Focus AG). In addition, the templates were characterized by scanning
electron microscopy (SEM). The template was adhered to specimen
stubs via carbon adhesive and sputter-coated with gold for 40 s
(BALZERS SCD 050 Sputter Coater, Germany). Imaging was
performed using a XL30 ESEM-FEG microscope (Philips, Nether-
lands) in high-vacuum mode using accelerating voltages of 10 kV.
Cryogel Synthesis. Cryogels were fabricated within the channels
of polystyrene templates, where each sheet could produce between 30
and 70 cryogels depending on the channel width used. In order to
incorporate heparin into the cryogel structure, heparin that had been
modified to contain six maleimide groups per heparin molecule was
used (henceforth termed heparin maleimide). The modification of the
heparin by linking maleimide amine to the heparins’ carboxylic acid
groups using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide
(EDC) and N-hydroxysulfo-succinimide (sNHS) was reported
previously.12
The polystyrene template was first treated with low-pressure
oxygen plasma (PDC-002, Harrick Plasma, USA) for 60 s to increase
the wettability of the template. A precursor solution was prepared
fresh prior to use, containing polyethylene glycol diacrylate (PEGDA)
of an average molecular weight of 700 Da (Sigma) at 0.1 g/mL,
heparin maleimide at 0.1 g/mL (molar ratio 1:0.05 PEGDA/heparin
maleimide), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)
(0.2 mg/mL) as a photoinitiator, and ATTO 610 maleimide (ATTO-
TEC, Germany) (0.1% v/v) as a fluorescent dye. A 4 μL aliquot of
this solution was added to the template, which filled the channels.
Excess was removed by drawing a polystyrene sheet across the top of
the template (see Figure 1). The template was then placed at −20 °C
for 30 min before being exposed to UV light (8 W hand lamp,
wavelength 254 nm, Benda, Wiesloch) for 3 min while still at −20 °C.
The cryogels were left to thaw, and since the polystyrene templates
are clear, the cryogels were also visualized at this stage via light
microscopy and fluorescence microscopy. SEM analysis was also
performed for cryogels left within the template.
The microscale cryogels were harvested from their template by
dissolving the template in 1 mL of tetrahydrofuran (THF) (Sigma).
After 2 min of gentle shaking, the cryogels parted from the template
and were transferred by pipet to a preweighed centrifuge tube, where
they were washed four times with THF (to remove dissolved
polystyrene), three times with water (to remove THF), and twice
with absolute ethanol (Sigma) and left to dry in a vacuum oven. The
filled centrifuge tubes were then reweighed to obtain the dry mass of
the cryogels.
Cryogel Characterization. Spinning disc confocal laser micros-
copy (SPCLM) was used to visualize the cryogels and measure the
pore size in the hydrated state. A Dragonfly SPCLM (Andor
Technology, U.K.) mounted on an Nikon Ti-E inverted microscope
was used with a 637 nm laser diode, and images were taken with
either a 10× magnification objective (CFI Plan Apo Lambda, Nikon)
or a 20× magnification objective (CFI Plan Apo Lambda, Nikon).
Pore sizes were analyzed from a single z-plane by measuring 100 pores
in both the x- and y-planes using ImageJ software (NIH). Where a
stack of z-planes was imaged, a z-distance of 0.5 μm was used. To
confirm the incorporation of heparin maleimide, cryogels were
synthesized as described above but without the inclusion of the
fluorescent label. Raman spectroscopy analysis of the PEGDA
monomer, heparin maleimide, cross-linked PEGDA, and the PEG/
heparin cryogels was performed using the Confocal Raman Micro-
scope alpha 300 R (WITec GmbH, Germany) equipped with a laser
with an excitation wavelength of 785 nm and a laser power of 500
μW. Samples were measured with a 20× objective (Zeiss) and an
integration time of 0.5 s for a single scan in the wavelength region
from 660 to 1850 cm−1. For each spectrum, 200 accumulations were
performed.
Growth Factor Loading and Release Analysis. Cryogels were
dried on a 0.4 μm hanging cell culture insert (n = 3 inserts of
cryogels) and weighed. The dried cryogels were resuspended in nerve
growth factor (human β-NGF), PeproTech, Germany) dissolved in
phosphate buffered saline (PBS) at a concentration of 5 ng/mL
(termed the loading solution). The amount of loading solution added
was calculated to accomplish a NGF to cryogel weight ratio of either
500 ng/mg of cryogel or 1000 ng/mg of cryogel (n = 3). In addition,
three culture inserts containing no cryogels (termed “empty” inserts)
were filled with 300 μL of 5 ng/mL of NGF to act as a control when
determining the percentage of NGF loaded to the cryogels. The
cryogels in the loading solution and the control loading solution were
left for 72 h at 37 °C in a sealed well plate. This loading solution was
then removed (by centrifuging the plate containing the insets at 1000
rpm for 1 min (2−16KL Sigma Centrifuges, Germany) and frozen at
−80 °C for subsequent analysis. The cryogels were washed with 600
μL of PBS per culture insert, and the wash solution was also retained
for analysis. The removed wash solution was replaced with 600 μL of
PBS. The cryogels were incubated at 37 °C, and at each time point (1,
3, 5, 7, 10, and 14 days), the solution was centrifuged through the
culture insert, removed, and stored at −80 °C and replaced by 600 μL
of fresh PBS. After 14 days, all stored samples were defrosted, and 100
μL of each sample was analyzed using an NGF enzyme-linked
immunosorbent assay (ELISA) (human β-NGF, DuoSet, R&D
Systems, Germany) according to the manufacturer’s instructions.
Dilutions were made where necessary to ensure that the sample
concentrations fell within standard curve obtained via the provided
standard protein. The percentage of loaded NGF was determined by
subtracting the loading solution and wash solution from the value of
NGF from the “empty” inserts. The results were plotted as cumulative
release with the standard deviation for each time point cumulated.
PC12 Cell Culture and Neurite Outgrowth Analysis. PC12
pheochromocytoma cells were cultured in Dulbecco’s modified eagle’s
medium (DMEM, Gibco−cat# 31966-021, Germany) at 37 °C and
5% CO2 using standard sterile cell culture techniques and seeded at a
density of 2500 cells per well in a poly-D-lysine (Sigma)-coated glass-
bottom 24-well plate. These were left overnight to attach, and the
media was supplemented with either NGF in PBS to create a final
concentration of 50 ng/mL (positive control) or an equal volume of
PBS (therefore 0 ng/mL of NGF, negative control), 1 mg of cryogels
loaded with 1000 ng/mL of NGF, or 1 mg of cryogels that were not
loaded with NGF (n = 3 for each group). The cells were imaged by
light microscopy (Olympus IX73) and then incubated at 37 °C, 5%
CO2 for 5 days. The high concentration of 50 ng/mL (positive
control) was used as a well-validated concentration for causing PC12
cell neurite outgrowth.49
After the incubation, the cells were once again imaged by light
microscopy and then washed carefully (so as not to remove the
cryogels from the well) and fixed with 4% formaldehyde for 10 min.
The cells were permeabilized with 1% Triton x-100 in PBS with 3%
goat serum (60 mg/mL, Jackson Immunoresearch, U.K.), 0.1%
HEPES (1M, Gibco). This solution was removed and replaced with
anti-βIII-tubulin antibody (raised in rabbit, diluted 1:1000 in blocking
solution − BioLegend, #802001, Germany) and incubated at 4 °C
overnight. The samples were then washed three times with PBS and
incubated for 3 h with a goat anti-rabbit secondary antibody
fluorescently labeled with Alexa 488 (Life Technologies #A11008,
Germany) at a 1:200 dilution in blocking solution. During the last 5
min of incubation, the Hoechst nucleic acid (nuclear) stain was added
at a dilution of 1:1000. The samples were then washed three times
with PBS and imaged by means of the Dragonfly SPCLM using the
405, 488, and 637 nm laser diodes. A total of 20 images were taken
per group from the three well replicates, and the lengths of the longest
neurites were measured50 (up to a total of 100 cells) using the
NeuronJ plugin for ImageJ (NIH software).
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acschemneuro.1c00005.
Additional data including template characterization,
cryogel characterization, images of injection, and
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://doi.org/10.1021/acschemneuro.1c00005
ACS Chem. Neurosci. 2021, 12, 1178−1188
1185




Ben Newland − Leibniz-Institut für Polymerforschung Dresden
e.V., Max Bergmann Center of Biomaterials Dresden, D-
01069 Dresden, Germany; School of Pharmacy and




Heike Newland − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany
Francesca Lorenzi − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany; Dipartimento di
Scienze Chimiche, Universita ̀ degli Studi di Padova, 135131
Padova, Italy
Dimitri Eigel − Leibniz-Institut für Polymerforschung Dresden
e.V., Max Bergmann Center of Biomaterials Dresden, D-
01069 Dresden, Germany
Petra B. Welzel − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany
Dieter Fischer − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany
Wenxin Wang − Charles Institute for Dermatology, University
College Dublin, Dublin D04 V1W8, Ireland; orcid.org/
0000-0002-5053-0611
Uwe Freudenberg − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany; orcid.org/0000-
0002-1359-1095
Anne Rosser − Brain Repair Group, School of Biosciences and
Brain Repair And Intracranial Neurotherapeutics (BRAIN)
Unit, Neuroscience and Mental Health Research Institute,
Cardiff University, Cardiff CF10 3AX, U.K.
Carsten Werner − Leibniz-Institut für Polymerforschung
Dresden e.V., Max Bergmann Center of Biomaterials
Dresden, D-01069 Dresden, Germany
Complete contact information is available at:
https://pubs.acs.org/10.1021/acschemneuro.1c00005
Author Contributions
Conceptualization − B.N.; Funding acquisition − B.N.;
Investigation − B.N., H.N., F.L., D.E., and D.F.; Methodology
− B.N., H.N., F.L., and D. E.; Resources − C.W.; Supervision
− P.B.W., W.W., U.F., A.R., and C.W.; Visualization − B.N.;
Writing − B.N.; Writing−review and editing − B.N., H.N.,
F.L., D.E., P.B.W., W.W., U.F., A.R., and C.W.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
B.N. would like to thank Parkinson’s UK (Innovation Grant),
the Wellcome Trust Sir Henry Wellcome Postdoctoral
Fellowship, and the Deutsche Forschungsgemeinschaft (Proj-
ect number 320041273) for funding. The authors would like to
thank Prof. Silvia Gross, Department of Chemical Sciences,
University of Padova, for additional supervision of F.L.
■ REFERENCES
(1) Eyjolfsdottir, H., Eriksdotter, M., Linderoth, B., Lind, G.,
Juliusson, B., Kusk, P., Almkvist, O., Andreasen, N., Blennow, K.,
Ferreira, D., Westman, E., Nennesmo, I., Karami, A., Darreh-Shori, T.,
Kadir, A., Nordberg, A., Sundström, E., Wahlund, L.-O., Wall, A.,
Wiberg, M., Winblad, B., Seiger, Å., Wahlberg, L., and Almqvist, P.
(2016) Targeted delivery of nerve growth factor to the cholinergic
basal forebrain of Alzheimer’s disease patients: application of a
second-generation encapsulated cell biodelivery device. Alzheimer's
Res. Ther. 8, 30.
(2) Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia,
S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., Longpre, L.,
Barclay, C. L., Boiko, C., Johnson, G. A., Fibiger, H. C., Harrison, R.,
Lewis, O., Pritchard, G., Howell, M., Irving, C., Johnson, D., Kinch, S.,
Marshall, C., Lawrence, A. D., Blinder, S., Sossi, V., Stoessl, A. J.,
Skinner, P., Mohr, E., and Gill, S. S. (2019) Randomized trial of
intermittent intraputamenal glial cell line-derived neurotrophic factor
in Parkinson’s disease. Brain 142, 512−525.
(3) Whone, A. L., Boca, M., Luz, M., Woolley, M., Mooney, L.,
Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U.,
Longpre, L., Barclay, C. L., Boiko, C., Johnson, G. A., Fibiger, H. C.,
Harrison, R., Lewis, O., Pritchard, G., Howell, M., Irving, C., Johnson,
D., Kinch, S., Marshall, C., Lawrence, A. D., Blinder, S., Sossi, V.,
Stoessl, A. J., Skinner, P., Mohr, E., and Gill, S. S. (2019) Extended
treatment with glial cell line-derived neurotrophic factor in
Parkinson’s disease. J. Parkinson's Dis. 9, 301−313.
(4) Kang, C. E., Baumann, M. D., Tator, C. H., and Shoichet, M. S.
(2013) Localized and sustained delivery of fibroblast growth factor-2
from a nanoparticle-hydrogel composite for treatment of spinal cord
injury. Cells Tissues Organs 197, 55−63.
(5) Barua, N. U., Gill, S. S., and Love, S. (2014) Convection-
enhanced drug delivery to the brain: Therapeutic potential and
neuropathological considerations. Brain Pathol. 24, 117−127.
(6) Moshayedi, P., Nih, L. R., Llorente, I. L., Berg, A. R.,
Cinkornpumin, J., Lowry, W. E., Segura, T., and Carmichael, S. T.
(2016) Systematic optimization of an engineered hydrogel allows for
selective control of human neural stem cell survival and differentiation
after transplantation in the stroke brain. Biomaterials 105, 145−155.
(7) Freudenberg, U., Hermann, A., Welzel, P. B., Stirl, K., Schwarz,
S. C., Grimmer, M., Zieris, A., Panyanuwat, W., Zschoche, S.,
Meinhold, D., Storch, A., and Werner, C. (2009) A star-PEG−heparin
hydrogel platform to aid cell replacement therapies for neuro-
degenerative diseases. Biomaterials 30, 5049−5060.
(8) Liang, Y., and Kiick, K. L. (2014) Heparin-functionalized
polymeric biomaterials in tissue engineering and drug delivery
applications. Acta Biomater. 10, 1588−1600.
(9) Freudenberg, U., Liang, Y., Kiick, K. L., and Werner, C. (2016)
Glycosaminoglycan-based biohybrid hydrogels: A sweet and smart
choice for multifunctional biomaterials. Adv. Mater. 28, 8861−8891.
(10) Welzel, P. B., Grimmer, M., Renneberg, C., Naujox, L.,
Zschoche, S., Freudenberg, U., and Werner, C. (2012) Macroporous
starPEG-heparin cryogels. Biomacromolecules 13, 2349−2358.
(11) Newland, B., Welzel, P. B., Newland, H., Renneberg, C., Kolar,
P., Tsurkan, M., Rosser, A., Freudenberg, U., and Werner, C. (2015)
Tackling cell transplantation anoikis: an injectable, shape memory
cryogel microcarrier platform material for stem cell and neuronal cell
growth. Small 11, 5047−5053.
(12) Tsurkan, M. V., Chwalek, K., Prokoph, S., Zieris, A., Levental,
K. R., Freudenberg, U., and Werner, C. (2013) Defined polymer−
peptide conjugates to form cell-instructive starPEG−heparin matrices
in situ. Adv. Mater. 25, 2606−2610.
(13) Sideris, E., Griffin, D. R., Ding, Y., Li, S., Weaver, W. M., Di
Carlo, D., Hsiai, T., and Segura, T. (2016) Particle hydrogels based on
hyaluronic acid building blocks. ACS Biomater. Sci. Eng. 2, 2034−
2041.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://doi.org/10.1021/acschemneuro.1c00005
ACS Chem. Neurosci. 2021, 12, 1178−1188
1186
(14) Griffin, D. R., Weaver, W. M., Scumpia, P. O., Di Carlo, D., and
Segura, T. (2015) Accelerated wound healing by injectable micro-
porous gel scaffolds assembled from annealed building blocks. Nat.
Mater. 14, 737−744.
(15) Koshy, S. T., Ferrante, T. C., Lewin, S. A., and Mooney, D. J.
(2014) Injectable, porous, and cell-responsive gelatin cryogels.
Biomaterials 35, 2477−2487.
(16) Bencherif, S. A., Sands, R. W., Bhatta, D., Arany, P., Verbeke, C.
S., Edwards, D. A., and Mooney, D. J. (2012) Injectable preformed
scaffolds with shape-memory properties. Proc. Natl. Acad. Sci. U. S. A.
109, 19590−19595.
(17) Liu, W., Li, Y., Zeng, Y., Zhang, X., Wang, J., Xie, L., Li, X., and
Du, Y. (2014) Microcryogels as injectable 3-D cellular microniches
for site-directed and augmented cell delivery. Acta Biomater. 10,
1864−1875.
(18) Eigel, D., Zoupi, L., Sekizar, S., Welzel, P. B., Werner, C.,
Williams, A., and Newland, B. (2019) Cryogel scaffolds for regionally
constrained delivery of lysophosphatidylcholine to central nervous
system slice cultures: A model of focal demyelination for multiple
sclerosis research. Acta Biomater. 97, 216−229.
(19) Eigel, D., Schuster, R., Männel, M. J., Thiele, J., Panasiuk, M. J.,
Andreae, L. C., Varricchio, C., Brancale, A., Welzel, P. B., Huttner, W.
B., Werner, C., Newland, B., and Long, K. R. (2021) Sulfonated
cryogel scaffolds for focal delivery in ex-vivo brain tissue cultures.
Biomaterials 271, 120712.
(20) Zoupi, L., Booker, S. A., Eigel, D., Werner, C., Kind, P. C.,
Spires-Jones, T. L., Newland, B., and Williams, A. C. (2021) Selective
vulnerability of inhibitory networks in multiple sclerosis. Acta
Neuropathol. 141, 415−429.
(21) Béduer, A., Braschler, T., Peric, O., Fantner, G. E., Mosser, S.,
Fraering, P. C., Benchérif, S., Mooney, D. J., and Renaud, P. (2015) A
compressible scaffold for minimally invasive delivery of large intact
neuronal networks. Adv. Healthcare Mater. 4, 301−312.
(22) Newland, B., Ehret, F., Hoppe, F., Eigel, D., Pette, D., Newland,
H., Welzel, P. B., Kempermann, G., and Werner, C. (2020)
Macroporous heparin-based microcarriers allow long-term 3D culture
and differentiation of neural precursor cells. Biomaterials 230, 119540.
(23) Schweitzer, J. S., Song, B., Leblanc, P. R., Feitosa, M., Carter, B.
S., and Kim, K.-S. (2020) Columnar injection for intracerebral cell
therapy. Oper. Neurosurg. 18, 321−328.
(24) Brecknell, J., Du, J., Muir, E., Fidler, P., Hlavin, M., Dunnett, S.,
and Fawcett, J. (1996) Bridge grafts of fibroblast growth factor-4-
secreting schwannoma cells promote functioal axonal regeneration in
the nigrostriatal pathway of the adult rat. Neuroscience 74, 775−784.
(25) Newland, B., Wolff, P., Zhou, D., Wang, W., Zhang, H., Rosser,
A., Wang, W., and Werner, C. (2016) Synthesis of ROS scavenging
microspheres from a dopamine containing poly (β-amino ester) for
applications for neurodegenerative disorders. Biomater. Sci. 4, 400−
404.
(26) Newland, B., Varricchio, C., Körner, Y., Hoppe, F., Taplan, C.,
Newland, H., Eigel, D., Tornillo, G., Pette, D., Brancale, A., Welzel, P.
B., Seib, F. P., and Werner, C. (2020) Focal drug administration via
heparin-containing cryogel microcarriers reduces cancer growth and
metastasis. Carbohydr. Polym. 245, 116504.
(27) Van Vlierberghe, S., Cnudde, V., Dubruel, P., Masschaele, B.,
Cosijns, A., De Paepe, I., Jacobs, P. J., Van Hoorebeke, L., Remon, J.
P., and Schacht, E. (2007) Porous gelatin hydrogels: 1. Cryogenic
formation and structure analysis. Biomacromolecules 8, 331−337.
(28) Ucar, B., and Humpel, C. (2019) Therapeutic efficacy of glial
cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo
organotypic brain slice Parkinson’s disease models. Brain Res. Bull.
149, 86−95.
(29) Ucar, B., Kajtez, J., Foidl, B. M., Eigel, D., Werner, C., Long, K.
R., Emnéus, J., Bizeau, J., Lomora, M., Pandit, A., Newland, B., and
Humpel, C. (2021) Biomaterial based strategies to reconstruct the
nigrostriatal pathway in organotypic slice co-cultures. Acta Biomater.
121, 250−262.
(30) Schurig, K., Zieris, A., Hermann, A., Freudenberg, U., Heidel,
S., Grimmer, M., Storch, A., and Werner, C. (2015) Neurotropic
growth factors and glycosaminoglycan based matrices to induce
dopaminergic tissue formation. Biomaterials 67, 205−213.
(31) Wood, M. D., and Sakiyama-Elbert, S. E. (2008) Release rate
controls biological activity of nerve growth factor released from fibrin
matrices containing affinity-based delivery systems. J. Biomed. Mater.
Res., Part A 84A, 300−312.
(32) Sakiyama-Elbert, S. E., and Hubbell, J. A. (2000) Controlled
release of nerve growth factor from a heparin-containing fibrin-based
cell ingrowth matrix. J. Controlled Release 69, 149−158.
(33) Guroff, G. (1985) PC12 cells as a model of neuronal
differentiation. Cell culture in the neurosciences, 245−272.
(34) Newland, B., Ehret, F., Hoppe, F., Eigel, D., Pette, D., Newland,
H., Welzel, P. B., Kempermann, G., and Werner, C. (2020) Static and
dynamic 3D culture of neural precursor cells on macroporous cryogel
microcarriers. MethodsX 7, 100805.
(35) Gvaramia, D., Müller, E., Müller, K., Atallah, P., Tsurkan, M.,
Freudenberg, U., Bornhäuser, M., and Werner, C. (2017) Combined
influence of biophysical and biochemical cues on maintenance and
proliferation of hematopoietic stem cells. Biomaterials 138, 108−117.
(36) Krieger, J. R., Ogle, M. E., McFaline-Figueroa, J., Segar, C. E.,
Temenoff, J. S., and Botchwey, E. A. (2016) Spatially localized
recruitment of anti-inflammatory monocytes by SDF-1α-releasing
hydrogels enhances microvascular network remodeling. Biomaterials
77, 280−290.
(37) Limasale, Y. D. P., Atallah, P., Werner, C., Freudenberg, U., and
Zimmermann, R. (2020) Tuning the local availability of VEGF within
glycosaminoglycan-based hydrogels to modulate vascular endothelial
cell morphogenesis. Adv. Funct. Mater. 30, 2000068.
(38) Newland, B., Newland, H., Werner, C., Rosser, A., and Wang,
W. (2015) Prospects for polymer therapeutics in Parkinson’s disease
and other neurodegenerative disorders. Prog. Polym. Sci. 44, 79−112.
(39) Li, H., Ham, T. R., Neill, N., Farrag, M., Mohrman, A. E.,
Koenig, A. M., and Leipzig, N. D. (2016) A hydrogel bridge
incorporating immobilized growth factors and neural stem/progenitor
cells to treat spinal cord injury. Adv. Healthcare Mater. 5, 802−812.
(40) Shahriari, D., Koffler, J. Y., Tuszynski, M. H., Campana, W. M.,
and Sakamoto, J. S. (2017) Hierarchically ordered porous and high-
volume polycaprolactone microchannel scaffolds enhanced axon
growth in transected spinal cords. Tissue Eng., Part A 23, 415−425.
(41) Yao, L., Daly, W., Newland, B., Yao, S., Wang, W., Chen, B. K.
K., Madigan, N., Windebank, A., and Pandit, A. (2013) Improved
axonal regeneration of transected spinal cord mediated by multi-
channel collagen conduits functionalized with neurotrophin-3 gene.
Gene Ther. 20, 1149−1157.
(42) Schwieger, J., Hamm, A., Gepp, M. M., Schulz, A., Hoffmann,
A., Lenarz, T., and Scheper, V. (2020) Alginate-encapsulated brain-
derived neurotrophic factor−overexpressing mesenchymal stem cells
are a promising drug delivery system for protection of auditory
neurons. J. Tissue Eng. 11, 2041731420911313.
(43) Hoban, D. B., Newland, B., Moloney, T. C., Howard, L., Pandit,
A., and Dowd, E. (2013) The reduction in immunogenicity of
neurotrophin overexpressing stem cells after intra-striatal trans-
plantation by encapsulation in an in situ gelling collagen hydrogel.
Biomaterials 34, 9420−9429.
(44) Dunnett, S., Rogers, D., and Richards, S.-J. (1989) Nigrostriatal
reconstruction after 6-OHDA lesions in rats: combination of
dopamine-rich nigral grafts and nigrostriatal “bridge” grafts. Exp.
Brain Res. 75, 523−535.
(45) Newland, B., Dunnett, S. B., and Dowd, E. (2016) Targeting
delivery in Parkinson’s disease. Drug Discovery Today 21, 1313−1320.
(46) Brecknell, J. E., Haque, N. S. K., Du, J. S., Muir, E. M., Fidler, P.
S., Hlavinj, M. L., Fawcett, J. W., and Dunnett, S. B. (1996)
Functional and anatomical reconstruction of the 6-hydroxydopamine
lesioned nigrostriatal system of the adult rat. Neuroscience 71, 913−
925.
(47) Bjugstad, K., Lampe, K., Kern, D., and Mahoney, M. (2010)
Biocompatibility of poly (ethylene glycol)-based hydrogels in the
brain: An analysis of the glial response across space and time. J.
Biomed. Mater. Res., Part A 95A, 79−91.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://doi.org/10.1021/acschemneuro.1c00005
ACS Chem. Neurosci. 2021, 12, 1178−1188
1187
(48) Müller, E., Wang, W., Qiao, W., Bornhäuser, M., Zandstra, P.
W., Werner, C., and Pompe, T. (2016) Distinguishing autocrine and
paracrine signals in hematopoietic stem cell culture using a
biofunctional microcavity platform. Sci. Rep. 6, 31951.
(49) Hu, R., Cao, Q., Sun, Z., Chen, J., Zheng, Q., and Xiao, F.
(2018) A novel method of neural differentiation of PC12 cells by
using Opti-MEM as a basic induction medium. Int. J. Mol. Med. 41,
195−201.
(50) Abu-Rub, M. T., Newland, B., Naughton, M., Wang, W.,
McMahon, S., and Pandit, A. (2016) Non-viral xylosyltransferase-1
siRNA delivery as an effective alternative to chondroitinase in an in
vitro model of reactive astrocytes. Neuroscience 339, 267−275.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://doi.org/10.1021/acschemneuro.1c00005
ACS Chem. Neurosci. 2021, 12, 1178−1188
1188
